Rivastigmine in Chinese patients with subcortical vascular dementia

Vincent Mok1, Adrian Wong1, Simon Ho2, Thomas Leung1, Wynnie WM Lam2, Ka Sing Wong11Department of Medicine and Therapeutics; 2Department of Radiology and Organ Imaging, The Chinese University of Hong Kong, Shatin, Hong Kong, ChinaBackground: We explored the efficacy and tolerability of rivastigmine...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Vincent Mok, Adrian Wong, Simon Ho, Thomas Leung, Wynnie WM Lam, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2007
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/e2718048a3bb43938d742d2def7a6f37
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e2718048a3bb43938d742d2def7a6f37
record_format	dspace
spelling	oai:doaj.org-article:e2718048a3bb43938d742d2def7a6f372021-12-02T00:50:42ZRivastigmine in Chinese patients with subcortical vascular dementia1176-63281178-2021https://doaj.org/article/e2718048a3bb43938d742d2def7a6f372007-01-01T00:00:00Zhttp://www.dovepress.com/rivastigmine-in-chinese-patients-with-subcortical-vascular-dementia-a974https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Vincent Mok1, Adrian Wong1, Simon Ho2, Thomas Leung1, Wynnie WM Lam2, Ka Sing Wong11Department of Medicine and Therapeutics; 2Department of Radiology and Organ Imaging, The Chinese University of Hong Kong, Shatin, Hong Kong, ChinaBackground: We explored the efficacy and tolerability of rivastigmine among Chinese patients with subcortical vascular dementia.Methods: Forty subjects were randomized to either placebo (n = 20) or rivastigmine (n = 20) in a double-blind 26-week trial. Outcome measures were cognition (mini-mental state examination, frontal assessment battery), neuropsychiatric inventory (NPI), instrumental activities of daily living, clinical dementia rating scale, and adverse events.Results: No statistical significant benefit could be observed in the active group in any of the efficacy measures. A trend favoring active group was observed only in the NPI subscore of irritability (p = 0.066) and aberrant motor behavior (p = 0.068). Withdrawal rate was 30% and 15% in the active and placebo group, respectively.Conclusion: Among Chinese subcortical vascular dementia patients, there was no apparent cognitive benefit associated with use of rivastigmine over the 6 months period. A trend favoring rivastigmine was observed in certain behavioral measures. Rivastigmine was associated with more withdrawals relative to placebo.Keywords: rivastigmine, subcortical vascular dementia, Chinese Vincent MokAdrian WongSimon HoThomas LeungWynnie WM Lamet alDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2007, Iss Issue 6, Pp 943-948 (2007)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Vincent Mok Adrian Wong Simon Ho Thomas Leung Wynnie WM Lam et al Rivastigmine in Chinese patients with subcortical vascular dementia
description	Vincent Mok1, Adrian Wong1, Simon Ho2, Thomas Leung1, Wynnie WM Lam2, Ka Sing Wong11Department of Medicine and Therapeutics; 2Department of Radiology and Organ Imaging, The Chinese University of Hong Kong, Shatin, Hong Kong, ChinaBackground: We explored the efficacy and tolerability of rivastigmine among Chinese patients with subcortical vascular dementia.Methods: Forty subjects were randomized to either placebo (n = 20) or rivastigmine (n = 20) in a double-blind 26-week trial. Outcome measures were cognition (mini-mental state examination, frontal assessment battery), neuropsychiatric inventory (NPI), instrumental activities of daily living, clinical dementia rating scale, and adverse events.Results: No statistical significant benefit could be observed in the active group in any of the efficacy measures. A trend favoring active group was observed only in the NPI subscore of irritability (p = 0.066) and aberrant motor behavior (p = 0.068). Withdrawal rate was 30% and 15% in the active and placebo group, respectively.Conclusion: Among Chinese subcortical vascular dementia patients, there was no apparent cognitive benefit associated with use of rivastigmine over the 6 months period. A trend favoring rivastigmine was observed in certain behavioral measures. Rivastigmine was associated with more withdrawals relative to placebo.Keywords: rivastigmine, subcortical vascular dementia, Chinese
format	article
author	Vincent Mok Adrian Wong Simon Ho Thomas Leung Wynnie WM Lam et al
author_facet	Vincent Mok Adrian Wong Simon Ho Thomas Leung Wynnie WM Lam et al
author_sort	Vincent Mok
title	Rivastigmine in Chinese patients with subcortical vascular dementia
title_short	Rivastigmine in Chinese patients with subcortical vascular dementia
title_full	Rivastigmine in Chinese patients with subcortical vascular dementia
title_fullStr	Rivastigmine in Chinese patients with subcortical vascular dementia
title_full_unstemmed	Rivastigmine in Chinese patients with subcortical vascular dementia
title_sort	rivastigmine in chinese patients with subcortical vascular dementia
publisher	Dove Medical Press
publishDate	2007
url	https://doaj.org/article/e2718048a3bb43938d742d2def7a6f37
work_keys_str_mv	AT vincentmok rivastigmineinchinesepatientswithsubcorticalvasculardementia AT adrianwong rivastigmineinchinesepatientswithsubcorticalvasculardementia AT simonho rivastigmineinchinesepatientswithsubcorticalvasculardementia AT thomasleung rivastigmineinchinesepatientswithsubcorticalvasculardementia AT wynniewmlam rivastigmineinchinesepatientswithsubcorticalvasculardementia AT etal rivastigmineinchinesepatientswithsubcorticalvasculardementia
_version_	1718403469119848448

Rivastigmine in Chinese patients with subcortical vascular dementia

Ejemplares similares